Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.
The company's recently launched nucleic acid isolation and purification kit is just one of several new products the company hopes bring to the market over the next few years.
Ambry's new lab provides a streamlined, automated workflow that has allowed the company to triple its daily testing volume since it opened more than four months ago.
The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.
When molecular testing did affect the surgical plan, it often led to overtreatment, according to the Johns Hopkins University School of Medicine team.
OpGen will add a commercial data visualization portal to its CLIA testing service and launch an integrated product and services offering this year.
Researchers outlined nine regulatory research-related challenges to validating, advancing, and improving next-generation sequencing-based diagnostic tests.
RNA sequencing uncovered differentially expressed genes in individuals with Lyme disease at diagnosis, immediately after antibiotic treatment, and six months later.
The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.
The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.
In Nature this week: genetic history of HIV in the US, and more.
There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.
A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.
Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.